iStockAnalyst | Revlimid Gains New Lymphoma Indication Monthly Prescribing Reference The new indication approval is based on the results of a Phase 2, multicenter, single-arm, open-label study evaluating lenalidomide in patients (N=134) with MCL who had received prior treatment with rituximab, cyclophosphamide, an anthracycline (or ... FDA Approves Lenalidomide for the Treatment of Mantle Cell Lymphoma |
